http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104693257-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-073 |
| filingDate | 2015-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104693257-B |
| titleOfInvention | Gemcitabine derivative of benzenesulfonyl furazan modification and its production and use |
| abstract | It is the compound and its pharmaceutically acceptable salt shown in formula I the invention discloses gemcitabine derivative of a kind of benzenesulfonyl furazan modification and its production and use.According to Rational drug design principle and principle of hybridization; retaining gemcitabine clinical pharmacology activity simultaneously; using gemcitabine as lead compound; benzenesulfonyl furazan NO donors are coupled to the N4 bit aminos of gemcitabine respectively by different linking groups; the NO donator type gemcitabine derivatives of benzenesulfonyl furazan modification are synthesized, obtain, bioavilability more preferable compound more stronger than gemcitabine antitumor activity. |
| priorityDate | 2015-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 572.